Alcidion accorded preferred provider status in the UK
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Shares in Alcidion Group Ltd (ASX:ALC) traded nearly 10% higher on Tuesday morning after the company announced that it had been selected in the UK as the preferred provider for Dartford and Gravesham NHS Trust’s Electronic Prescription Medications Administration System.
Importantly, the award of preferred provider status resulted from a competitive tender process.
Upon final contract, Alcidion will deploy Better by Marand’s OPENeP platform, an electronic medication management system that is designed to prevent adverse medication related events.
In April 2019, Alcidion was appointed as a reseller partner by Better by Marand for the UK, Australia and New Zealand.
Alcidion managing director Kate Quirke noted that this was an endorsement of the group’s broader capabilities in saying, “We are delighted to extend our existing relationship with the Dartford and Gravesham NHS Trust.
Potential for further opportunities
‘’The selection of Alcidion demonstrates the breadth of our capabilities and our value as the Trust’s strategic partner to support its goal of being Paperless at the Point of Care by 2020.
“This is the first major tender for which Alcidion has been selected to supply the OPENeP platform.’’
The award of preferred provider status demonstrates the power of Alcidion’s expanded portfolio of complementary products and solutions that sit alongside Miya and Patientrack, enabling the group to offer a truly best-of-breed integrated solution that covers a wide range of clinical needs including next generation medications management.
This is subject to approval of the business case by the Trust Board and successful negotiation and final approval of a contract, which is expected in late 2019.
It should be noted that Alcidion does not normally announce the award of preferred provider status, however this information is considered material and likely to be shared beyond the Trust and Alcidion and hence has been released ahead of a final contract being signed.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
